JANX
Janux Therapeutics Inc

1,706
Mkt Cap
$830.65M
Volume
1.09M
52W High
$45.79
52W Low
$12.80
PE Ratio
-8.18
JANX Fundamentals
Price
$13.71
Prev Close
$13.83
Open
$13.82
50D MA
$17.57
Beta
1.48
Avg. Volume
3.23M
EPS (Annual)
-$1.28
P/B
0.84
Rev/Employee
$130,716.05
Loading...
Loading...
News
all
press releases
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of "Moderate Buy" by Brokerages
Shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the fifteen research firms that are currently covering the stock...
MarketBeat·9h ago
News Placeholder
More News
News Placeholder
Janux Therapeutics (NASDAQ:JANX) Shares Gap Down - Should You Sell?
Janux Therapeutics (NASDAQ:JANX) Shares Gap Down - Here's Why...
MarketBeat·6d ago
News Placeholder
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer
Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor...
Business Wire·6d ago
News Placeholder
JANX Enters Global Oncology Collaboration With BMY, Stock Rises
Janux Therapeutics struck a global licensing deal for its tumor-activated platforms, sending shares higher and expanding its reach in solid tumors.
Zacks·9d ago
News Placeholder
Janux Therapeutics (NASDAQ:JANX) Sees Strong Trading Volume - Here's Why
Janux Therapeutics (NASDAQ:JANX) Sees Unusually-High Trading Volume - Still a Buy...
MarketBeat·10d ago
News Placeholder
Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million
Janux Therapeutics signs a global licensing deal with Bristol Myers Squibb worth up to $800 million.read more...
Benzinga·10d ago
News Placeholder
Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb
The company, along with Bristol Myers Squibb, will develop a new tumor-activated therapy.
Stocktwits·10d ago
News Placeholder
Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor...
Business Wire·10d ago
News Placeholder
Clear Str Downgrades Janux Therapeutics (NASDAQ:JANX) to Hold
Clear Str cut shares of Janux Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Tuesday...
MarketBeat·11d ago
News Placeholder
Janux Therapeutics (NASDAQ:JANX) Reaches New 1-Year Low - What's Next?
Janux Therapeutics (NASDAQ:JANX) Hits New 1-Year Low - Here's Why...
MarketBeat·12d ago
<
1
2
...
>

Latest JANX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.